Menu
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward for the results of this research enabled by SOPHiA’s unique platform”
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma.”
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward for the results of this research enabled by SOPHiA’s unique platform”
Use one universal, automated protocol for robust sequencing across applications.
Match cancer genomic profiles to the most up-to date information with OncoPortal™ Knowledge Base.
Precisely detect challenging genomic variants with our proprietary algorithms.
Quickly prepare comprehensive reports tailored to your needs.
Sensitive SNV, Indel & TMB detection
Accurate CNV calling
Partner-agnostic fusion calling
Universal genomic integrity assessment
Pan-cancer MSI detection
Precise molecular barcoding
Robust variant annotation
| SOPHiA DDM™ HCS v1.1 (RUO) | SOPHiA DDM™ HCS v2.0 (RUO) | SOPHiA DDM™ Dx HCS (CE-IVD) | |
|---|---|---|---|
| Diseases covered | Hereditary Breast and Ovarian Cancer (HBOC), Lynch and various intestinal polyposis syndromes | Breast, ovarian, prostate, abdominal, endocrine & neuroendocrine, nervous system, renal, and skin | Breast and ovarian cancers and colorectal syndromes |
| Diseases covered | 26 + PMS2CL | 82 + PMS2CL | 26 + PMS2CL |
| Target region size | 105 kb | 285 kb | 105 kb |
| Sample type | Blood | Blood | Blood |
| DNA input amount | 200 ng | 50 ng | 200 ng |
| Sequence |
|
|
|
| Library prep time | 1.5 days | 1.5 days | 2 days |
| Analysis time from FASTQ | 4 hours | 4 hours | < 6 hours |
| Detected variants |
|
|
|
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
